The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2023-10-21
DOI
10.1080/17512433.2023.2274536
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis
- (2023) Stergios A. Polyzos et al. CURRENT MEDICINAL CHEMISTRY
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature
- (2023) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
- (2023) Manuel Romero-Gómez et al. JOURNAL OF HEPATOLOGY
- Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
- (2022) Mathias B Møllerhøj et al. CTS-Clinical and Translational Science
- Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
- (2022) A. Sidney Barritt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
- (2022) Cheng Han Ng et al. Clinical Gastroenterology and Hepatology
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
- (2022) Naim Alkhouri et al. JOURNAL OF HEPATOLOGY
- Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
- (2022) Stergios A. Polyzos et al. Current Obesity Reports
- Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
- (2022) Linda Henry et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer
- (2022) Stergios A. Polyzos et al. Hormones-International Journal of Endocrinology and Metabolism
- Circulating adiponectin in patients with nonalcoholic fatty liver disease‐related liver fibrosis: A systematic review and a meta‐analysis
- (2022) Christina Tontikidou et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Combination Therapies for Nonalcoholic Fatty Liver Disease
- (2022) Evangelia S. Makri et al. Journal of Personalized Medicine
- A systematic review and meta‐analysis of observational studies of the association between the use of incretin‐based therapies and the risk of pancreatic cancer
- (2022) Khemayanto Hidayat et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model
- (2021) Xiankang Fang et al. LIFE SCIENCES
- Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis
- (2021) Nikolaos Perakakis et al. LIVER INTERNATIONAL
- Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations
- (2021) Stergios A. Polyzos et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
- (2021) Abdul M. Majzoub et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist
- (2021) Rayane Miranda Pontes-da-Silva et al. INTERNATIONAL JOURNAL OF OBESITY
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Comparative effectiveness of cardiovascular, renal and safety outcomes of second‐line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta‐analysis of randomised controlled trials
- (2021) Ruth Sim et al. DIABETIC MEDICINE
- Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis
- (2021) Xuexue Zhang et al. Endocrine Practice
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
- (2020) Lin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2020) Ling-Yun Zhang et al. Clinics and Research in Hepatology and Gastroenterology
- Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet
- (2020) Ningjing Zhang et al. Biomed Research International
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
- (2020) Motoyasu Kojima et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
- (2020) Emmanuel Somm et al. Translational Research
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Glucagon Like Peptide-1 Receptor Agonists Alters Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model
- (2020) Taiyong Fang et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
- (2020) Evangelia Makri et al. ARCHIVES OF MEDICAL RESEARCH
- Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial
- (2020) Wen Guo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue
- (2019) Samuel J. Daniels et al. BIOMEDICINE & PHARMACOTHERAPY
- Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block
- (2019) Vasilios G. Athyros et al. Current Vascular Pharmacology
- Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis
- (2019) Thibaut Duparc et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis
- (2019) Vasiliki Venetsanaki et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials
- (2019) Mirna Abd El Aziz et al. DIABETES OBESITY & METABOLISM
- Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways
- (2019) Ying Luo et al. Drug Design Development and Therapy
- Pharmacotherapy of type 2 diabetes: An update
- (2018) Jagriti Upadhyay et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
- (2018) Kirstine S Tølbøl et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study
- (2018) Niina Matikainen et al. DIABETES OBESITY & METABOLISM
- Liraglutide modulates gut microbiota and reduces NAFLD in obese mice
- (2018) GV Moreira et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- (2018) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Emerging and future therapies for nonalcoholic steatohepatitis in adults
- (2016) Gesthimani Mintziori et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
- (2016) Jean-Michel Petit et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies
- (2016) Tai Wei et al. Oncotarget
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
- (2014) Hui Fan et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies
- (2014) Hwan-Woo Park et al. Autophagy
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
- (2014) Yuichiro Eguchi et al. HEPATOLOGY RESEARCH
- Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease
- (2014) Christine Bernsmeier et al. PLoS One
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
- (2012) James L. Trevaskis et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer
- (2012) Carlos Alves et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
- (2012) Wei-Yih Chiu et al. Experimental Diabetes Research
- Nonalcoholic Fatty Liver Disease
- (2012) Stergios A. Polyzos et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
- (2012) Takamasa Ohki et al. TheScientificWorldJOURNAL
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- GLP-1-derived nonapeptide GLP-1(28–36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes
- (2011) Eva Tomas et al. REGULATORY PEPTIDES
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
- (2010) Mary Parks et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease
- (2009) Stergios A. Polyzos et al. DIABETES OBESITY & METABOLISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started